Skip to main content
77°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Epizyme Inc
(NQ:
EPZM
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 11, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Epizyme Inc
< Previous
1
2
Next >
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From
Epizyme, Inc.
Via
Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
July 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
June 27, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
June 28, 2022
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...
Via
FinancialNewsMedia
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
June 27, 2022
From
Halper Sadeh LLP
Via
Business Wire
Ipsen to acquire Epizyme, expanding its portfolio in oncology
June 27, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
June 02, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme To Participate in H.C. Wainwright Global Investment Conference
May 17, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Date of First Quarter 2022 Financial Results
May 03, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
March 15, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Pricing of Public Offering of Common Stock
January 27, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Proposed Public Offering of Common Stock
January 26, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
January 10, 2022
From
Epizyme, Inc.
Via
Business Wire
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
December 12, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
December 11, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
December 02, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Updates to Its Board of Directors
November 18, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme to Participate in Jefferies London Healthcare Conference
November 12, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
November 09, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414
November 04, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Date of Third Quarter 2021 Financial Results
November 02, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making
November 01, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress
September 14, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2021
From
Epizyme, Inc.
Via
Business Wire
Epizyme Announces CEO Succession
August 09, 2021
From
Epizyme, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.